Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selgantolimod in Chronic Hepatitis B and HIV
NCT05551273Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of selgantolimod in hepatitis B (HBV), sponsored by National Institute of Allergy and Infectious Diseases. Started May 2023; status: completed.
02
Drugs
selgantolimod
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT05551273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05551273.